title: rh-BMP-2 can be used safely in the cervical spine: dose and containment are the keys!
authors.forename: Rob D
authors.initials: RD
authors.lastname: Dickerman
authors.forename: Ashley S
authors.initials: AS
authors.lastname: Reynolds
authors.forename: Brent C
authors.initials: BC
authors.lastname: Morgan
authors.forename: John
authors.initials: J
authors.lastname: Tompkins
authors.forename: Jeff
authors.initials: J
authors.lastname: Cattorini
authors.forename: Matthew
authors.initials: M
authors.lastname: Bennett
mesh_terms: D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002574:Cervical Vertebrae / Q000601:surgery*; D017586:Diskectomy / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000209:etiology; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013123:Spinal Fusion; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta